MolDX: Genetic Testing for Hereditary Thrombophilia

Genetic testing for hereditary (germline) thrombophilia—including LDTs, FDA-cleared/approved tests and NGS—is covered when the patient has VTE with qualifying non-surgical major transient or hormonal risk factors, or cerebral/splanchnic venous thrombosis where testing will inform the decision for long-term anticoagulation. Covered tests must include the minimum ASH-guideline-based genetic content necessary for clinical decision making, be properly validated, have completed the MolDX Technical Assessment, and single-variant testing is allowed only for known familial variants; tests with unvalidated or non-actionable content or those conflicting with repeat-testing policy L38274 are not covered.

"Genetic testing for hereditary thrombophilia (hereditary germline testing) is covered for lab-developed tests (LDTs), FDA-cleared, and FDA-approved clinical laboratory tests, including NGS, when al..."